Eisai/Biogen’s Leqembi Gets Some Medicare Coverage Certainty In CMS Update
Unclear If Registry Requirement Will Limit Patient Access
CMS said Medicare will cover anti-amyloid antibodies for early Alzheimer’s disease upon traditional approval from the US FDA if prescribed by doctors participating in a patient registry.